Alpha memo: glynac glycine acetylcysteine glutathione cross-context signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Identify and explicitly state the single bounded research signal the memo is trying to surface; the current 'cross-context signal' framing is not supported by a same-group preclinical/clinical pair.
2. Specify what in Receipt 2 actually bounds the human evidence (e.g., pilot trial design, n, lack of replication, missing hard endpoints), rather than asserting a boundary without evidence.
3. Rewrite the synthesis to compare the mouse brain study (Receipt 1) and human pilot trial (Receipt 2) on shared mechanisms (GSH, OxS, mitochondrial function, cognition) and identify whether, where, and why findings diverge or translate - this is required to make the memo more than a receipt listing.
4. Remove or replace the meaningless search metadata with a coherent, minimal search scope statement.
5. Acknowledge that both papers are from the Sekhar group and address how that affects independence of the signal.

Major issues

• The memo is framed as a 'cross-context signal' but the two receipts are from the same research group (Sekhar) and represent a direct preclinical-to-clinical translation by the same authors, not a cross-context contradiction or surprising reversal. The claimed 'translation_boundary' geometry is not established by the evidence.
• The one-sentence alpha claims Receipt 2 'forces the update that the human evidence is bounded by population or endpoint' but Receipt 2's own excerpt states GlyNAC improved strength, gait-speed, cognition, body composition, and multiple biomarkers in older adults. The memo does not identify what specifically bounds the human evidence - no failure endpoint, no null finding, no population limitation is surfaced.
• The memo offers no synthesized argument. It is a two-receipt summary with a vague 'Why this is surprising' note that does not engage with the actual content of either paper. There is no integration of methods, mechanisms, or results.
• The 'search receipt' metadata (hits=10, shards=1525/1525, papers_searched=1456919317) is incoherent and not interpretable, undermining confidence in the search methodology.

Minor issues

• Title is hyphenated awkwardly ('glynac glycine acetylcysteine glutathione cross-context signal') and does not clearly state the research signal.
• Caveats/falsifiers are generic and do not engage with the actual evidence content.
• No clear statement of what the bounded research signal is - the memo fails its own first review check ('makes one bounded, source-grounded research signal clear').

Reviewer note

Reject. The submission is titled and framed as a 'cross-context signal' alpha memo but delivers no identifiable bounded signal and no synthesis. The two receipts are a paired preclinical/clinical study from the same research group (Sekhar), which is not a cross-context surprise. The one-sentence alpha asserts that Receipt 2 'forces the update that the human evidence is bounded by population or endpoint' but Receipt 2's own excerpt reports broad positive findings across multiple endpoints in older adults; no specific bounding failure is identified. The body is a receipt listing plus a vague 'why this is surprising' note, with no integration of methods, mechanisms, or outcomes. Search metadata is incoherent. This memo fails its own stated review check of making 'one bounded, source-grounded research signal clear.' Reject rather than revise because the central claim (a cross-context translation boundary) is not actually supported by the source bundle and would require a scope reset, not bounded edits, to fix.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis